Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer

1 Nov 2020

Abstract excerpt

PURPOSE: Germ cell tumors (GCTs) are cured with therapy based on cisplatin, although a clinically significant number of patients are refractory and die of progressive disease. Based on preclinical studies indicating that refractory testicular GCTs are hypersensitive to hypomethylating agents (HMAs), we conducted a phase I trial combining the next-generation HMA guadecitabine (SGI-110) with cisplatin in recurrent,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Histone Deacetylase Inhibitors Research
Share to Testicular diseases and treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33135391
DOI: 10.1002/cam4.3583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancerPMID 33135391Read ↗

Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabineSemantic proximity Read ↗

Immunotherapy in Testicular Germ Cell TumorsSemantic proximity Read ↗

Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumorsSemantic proximity Read ↗

Epigenetic treatment combinations to effectively target cisplatin‐resistant germ cell tumors: past, present, and future considerationsSemantic proximity Read ↗

Targeting of Deregulated Wnt/β-Catenin Signaling by PRI-724 and LGK974 Inhibitors in Germ Cell Tumor Cell LinesSemantic proximity Read ↗

Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapySemantic proximity Read ↗

Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors.Semantic proximity Read ↗

Mirvetuximab Soravtansine Induces Potent Cytotoxicity and Bystander Effect in Cisplatin-Resistant Germ Cell Tumor CellsSemantic proximity Read ↗

Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo‐refractory germ cell tumorsSemantic proximity Read ↗

Identification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors.Semantic proximity Read ↗

Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumorsSemantic proximity Read ↗

Sunitinib in Patients with Cisplatin-Refractory Germ Cell TumorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.